Karen Lewis Biography and Net Worth

Karen joined Apellis in May 2020 as our chief people officer and brings over 20 years of experience leading human resource (HR) teams in the biotechnology and technology industries. She most recently led and built the HR function at Axcella Health, a start-up biotech company in the Boston area. Prior to Axcella, Karen held numerous leadership roles with increasing responsibility at Biogen including overseeing global talent acquisition, leading human resources for several commercial and market access functions, and managing HR for Asia Pacific and Latin America. Previously, Karen worked at Amazon and Bristol-Myers Squibb where she held leadership roles in talent acquisition, talent management and as an HR business leader supporting the R&D and commercial functions. Karen holds a B.S. in biology from Rider University and worked as a research scientist at a start-up biotech company before entering HR.

What is Karen Lewis' net worth?: The estimated net worth of Karen Lewis is at least $1.32 million as of June 1st, 2023. Ms. Lewis owns 41,504 shares of Apellis Pharmaceuticals stock worth more than $1,323,978 as of December 30th. This net worth estimate does not reflect any other investments that Ms. Lewis may own. Learn More about Karen Lewis' net worth.
How old is Karen Lewis?: Ms. Lewis is currently 51 years old. There are 6 older executives and no younger executives at Apellis Pharmaceuticals. The oldest executive at Apellis Pharmaceuticals is Mr. James G. Chopas CPA, VP, Corporate Controller & Chief Accounting Officer, who is 57 years old. Learn More on Karen Lewis' age.
How do I contact Karen Lewis?: The corporate mailing address for Ms. Lewis and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on Karen Lewis' contact information.
Has Karen Lewis been buying or selling shares of Apellis Pharmaceuticals?: Karen Lewis has not been actively trading shares of Apellis Pharmaceuticals during the past quarter. Most recently, Karen Lewis sold 5,000 shares of the business's stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $86.00, for a transaction totalling $430,000.00. Following the completion of the sale, the insider now directly owns 41,504 shares of the company's stock, valued at $3,569,344. Learn More on Karen Lewis' trading history.
Who are Apellis Pharmaceuticals' active insiders?: Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Apellis Pharmaceuticals?: During the last twelve months, insiders at the sold shares 30 times. They sold a total of 578,000 shares worth more than $32,475,747.36. The most recent insider tranaction occured on December, 23rd when insider Jeffrey Eisele sold 63 shares worth more than $2,084.67. Insiders at Apellis Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Apellis Pharmaceuticals.
Information on this page was last updated on 12/23/2024.

Karen Lewis Insider Trading History at Apellis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/1/2023	Sell	5,000	$86.00	$430,000.00	41,504
4/3/2023	Sell	5,000	$75.00	$375,000.00	41,430
1/23/2023	Sell	2,955	$51.58	$152,418.90	37,709

Karen Lewis Buying and Selling Activity at Apellis Pharmaceuticals

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $31.90

$31.88

$32.50

50 Day Range

MA: $30.84

$26.18

$35.42

2 Week Range

Now: $31.90

$24.34

$73.80

Volume

3,050,171 shs

Average Volume

1,994,316 shs

Market Capitalization

$3.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Kamala’s final humiliation

From Porter & Company | Ad

The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware of… yet have the potential to deliver colossal returns over the next four years. I’m not talking about Tesla, Palantir, or anything else you’ve heard parroted by the mainstream financial press. No. These are Trump’s Secret Stocks.

It’s all waiting for you here.

Karen Lewis Biography and Net Worth

What is Karen Lewis' net worth?

How old is Karen Lewis?

How do I contact Karen Lewis?

Has Karen Lewis been buying or selling shares of Apellis Pharmaceuticals?

Who are Apellis Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Apellis Pharmaceuticals?